- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 17,183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 303
- States / cities
- Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 370
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cluster Headache
- Interventions
- Fremanezumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
- Conditions
- Migraine
- Interventions
- Rizatriptan co-administered with Acetaminophen
- Drug
- Lead sponsor
- Diamond Headache Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 7
- States / cities
- San Francisco, California • Chicago, Illinois • Kalamazoo, Michigan + 4 more
- Conditions
- Respiratory Depression
- Interventions
- Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo
- Drug
- Lead sponsor
- BioDelivery Sciences International
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Postoperative Nausea and Vomiting (PONV)
- Interventions
- TAK-951, Ondansetron, Ondansetron Placebo, TAK-951 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Pasadena, California • Tamarac, Florida + 4 more
- Conditions
- Asthma
- Interventions
- MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
- Drug
- Lead sponsor
- Mylan Pharma UK Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
- Conditions
- Healthy, Memory Impairment
- Interventions
- AZD8529, Placebo to match AZD8529
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- zolpidem tartrate, sodium oxybate, Matching Placebos
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- COPD Exacerbation
- Interventions
- Formoterol, Placebo
- Drug · Other
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Lubiprostone, Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab, Adalimumab PRN, Placebo
- Drug
- Lead sponsor
- Peter Higgins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis
- Interventions
- Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
- Conditions
- Plaque-type Psoriasis
- Interventions
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
- Conditions
- Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
- Interventions
- Haloperidol + lorazepam, Loxapine
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 12 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- ThermoDox, Dummy infusion
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Asthma
- Interventions
- Fluticasone propionate, Placebo, BI 54903
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 41
- States / cities
- Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
- Conditions
- Hypertension
- Interventions
- Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 101
- States / cities
- Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 87
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 77 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
- Conditions
- Infertility
- Interventions
- Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution
- Drug
- Lead sponsor
- IBSA Institut Biochimique SA
- Industry
- Eligibility
- 35 Years to 42 Years · Female only
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 24
- States / cities
- Tempe, Arizona • Encino, California • Los Angeles, California + 20 more
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- Eravacycline, Ertapenem, Placebo, Levofloxacin
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Fullerton, California • Los Angeles, California • Torrance, California + 7 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Glendale, Arizona • San Jose, California + 18 more
- Conditions
- Heart Failure
- Interventions
- Placebo, Amiloride, Bendroflumethiazide
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut